Reacta Healthcare Announces the Appointment of Iedena Lima as Head of Research and Development

Deeside, UK, 10 August 2026  

Reacta Healthcare, announces the appointment of Iedena Lima as Head of Research and Development (R&D). She will also serve as a member of the company’s Senior Leadership Team.

Iedena brings more than 20 years of pharmaceutical development and leadership experience across formulation development, regulatory strategy, process validation, and commercial product development within GMP-regulated environments. At Reacta she will lead the continued evolution of the company’s R&D function as it expands the product portfolio and global clinical trial support capabilities.

Iedena joins from Wockhardt UK, where she held a number of senior R&D leadership roles, most recently serving as Head of Research and Development. During her career, she has led global development programmes supporting product approvals across global markets, while driving improvements in development efficiency, technical governance, and cross-functional integration. Previous experience includes senior positions at Advanced Woundcare and Hikma Pharmaceuticals.

Paul Abrahams, CEO of Reacta Healthcare said: “I am delighted to welcome Iedena to the team. Her appointment supports Reacta’s long-term strategy to strengthen and scale our development function, support international growth, and further position the company at the forefront of food allergy diagnostics and clinical research.”

Iedena Lima, Head of Research and Development of Reacta Healthcare said:

“Reacta is already a leader in applying pharmaceutical industry standards to improve the safety, accuracy and efficiency of food allergy testing. I look forward to working with the team to develop our portfolio and serve the growing customer base for our OFC products which play a vital role in the development of therapies and diagnostics to transform the lives of the millions of people living with food allergy worldwide.”